Appointment of Director

RNS Number : 6071C

Venn Life Sciences Holdings PLC

19 October 2015

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

Appointment of Director

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that following the completion of the acquisition of Kinesis Pharma B.V. ("Kinesis"), Mr Kees Groen, has been appointed as an Executive Director of Venn with immediate effect.

Mr Groen, aged 54, is a founder and managing director of Kinesis, and is a regulatory expert with significant experience in pharmaceutical research and development, both with regulatory authorities and in industry. He has been involved on a management and operational level in the fields of preclinical and clinical development, regulatory affairs and licensing for 25 years.

Tony Richardson, Chief Executive Officer of Venn said: "Keess' vast experience in all aspects of drug development will bring significant value to Venn Life Sciences. This appointment will add capability and capacity which will allow us to explore further acquisition opportunities. With this we can continue to build a successful and sustainable business for shareholders."

Information pursuant to Schedule Two, paragraph (g) of the AIM Rules is set out below:-

Mr Groen is beneficially interested in 4,780,320 ordinary shares in the Company, amounting to 8.03% of the issued share capital of the Company as part consideration for the purchase of Kinesis and are subject to a lock up period of 12 months from 16 October 2015.

Current directorships or partnerships	Directorships or partnerships in the last five years
Oriental Flavour Investments BV	InPEC BV
G&G Life Sciences BV
Brant Life Sciences BV
Cinmar Pharma BV
Dieze Delta BV
Orca therapeutics BV

Mr Groen was a member of the Advisory Board of InPEC B.V a Phase 1 CRO, a company invested in by Kinesis Holding. InPEC was liquidated on 20 April 2010.

Save as disclosed above, there are no further disclosures required to be made in respect of the appointment under Schedule 2(g) of the AIM Rules for Companies.

Enquiries:

Venn Life Sciences Holdings Plc
David Evans, Non-Executive Chairman		Tel: [phone]
Tony Richardson, Chief Executive Officer		Tel: [phone]
Zeus Capital (Nominated Adviser and Co-Broker)
Andrew Jones/Phil Walker		Tel: [phone]
Dominic Wilson/Alex Davies		Tel: [phone]
Hybridan LLP (Co-Broker) Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus		Mob: [phone]
Lianne Cawthorne		Mob: [phone]

About Venn Life Sciences:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

END

 

 

MSCUWRKRVNARAAA